SAVE THE DATE - Society John F Wilkinson Lecture - Wednesday 7th May 2025- Dr Mark Saunders '"Recent evolution of immunotherapy in colorectal cancer"
02 . 04 . 25
Venue: MANDEC, Higher Cambridge Street, Manchester M15 6FH
5.30 pm
Coffee and registration
6.00 - 7.00 pm
Dr Mark Saunders, Consultant Clinical Oncologist, The Christie NHS Foundation Trust
Learning points:
- There are an increasing number of treatments that are able to manipulate a patient’s immune system for therapeutic gain
- Immunotherapies, such as checkpoint inhibitors nearly failed in colorectal cancer until, perhaps by chance, it became evident that certain subsets benefit much more than others.
- Single agent and combination immunotherapies are now used routinely in deficient mismatch repair colorectal cancer and to put in bluntly, are a “game-changer”
- Immune manipulation is now being used in other, much more common subsets, to hopefully benefit a much wider group of patients
- But, how long do we give them and can the world afford them?
Dr Saunders' main area of interest is running clinical trials evaluating novel agents with associated response/toxicity biomarkers and radiology (colorectal cancer, anal cancer, stomach chemoradiotherapy and pseudomyxoma). He is a member of a number of National Cancer Research Network (NCRN) CRC committees and works with SchAAR to prepare material for the National Institute for Health and Care Excellence (NICE).
He has written a series of protocols for clinical trials that have been funded, completed and published. He chairs or is a member of a number of trial management groups and data-monitoring committees. He is also an advisor to Beating Bowel Cancer, a charity dedicated to raising awareness of bowel cancer, improving the quality of life of those affected and, ultimately, reducing deaths from bowel cancer.
All attendees will receive a CPD certificate - RCP credit applied for
View Other News